{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"data_sharing_plan":["IPD Sharing (as of August 2023): No\nDescription: Data will not be shared according to the Sponsor policy on data sharing. Taiho policy on data sharing may be found at https://www.taiho.co.jp/en/science/policy/clinical_trial_information_disclosure_policy/index.html."],"condition":["Adenocarcinoma","Advanced or Metastatic Solid Tumor","Colorectal Cancer","Non-small Cell Lung Cancer","Gastric Cancer","Pancreatic Ductal Adenocarcinoma"],"disease":["Adenocarcinoma","Colorectal Cancer","Non-small Cell Lung Cancer","Gastric Cancer","Advanced Or Metastatic Solid Tumor","Pancreatic Ductal Adenocarcinoma"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2386215"],"location":["Japan"],"study_start_month":["6"],"keyword":["Ramucirumab","Futibatinib","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"AB122 Platform Study","description":"This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.","dates":{"creation":"2021-06-15"},"accession":"2386215","cross_references":{"ClinicalTrials___gov":["NCT04999761"]}}